Nuclear alpha1-adrenergic receptors signal activated ERK localization to caveolae in adult cardiac myocytes.
We previously identified an alpha1-AR-ERK (alpha1A-adrenergic receptor-extracellular signal-regulated kinase) survival signaling pathway in adult cardiac myocytes. Here, we investigated localization of alpha1-AR subtypes (alpha1A and alpha1B) and how their localization influences alpha1-AR signaling in cardiac myocytes. Using binding assays on myocyte subcellular fractions or a fluorescent alpha1-AR antagonist, we localized endogenous alpha1-ARs to the nucleus in wild-type adult cardiac myocytes. To clarify alpha1 subtype localization, we reconstituted alpha1 signaling in cultured alpha1A- and alpha1B-AR double knockout cardiac myocytes using alpha1-AR-green fluorescent protein (GFP) fusion proteins. Similar to endogenous alpha1-ARs and alpha1A- and alpha1B-GFP colocalized with LAP2 at the nuclear membrane. alpha1-AR nuclear localization was confirmed in vivo using alpha1-AR-GFP transgenic mice. The alpha1-signaling partners Galphaq and phospholipase Cbeta1 also colocalized with alpha1-ARs only at the nuclear membrane. Furthermore, we observed rapid catecholamine uptake mediated by norepinephrine-uptake-2 and found that alpha1-mediated activation of ERK was not inhibited by a membrane impermeant alpha1-blocker, suggesting alpha1 signaling is initiated at the nucleus. Contrary to prior studies, we did not observe alpha1-AR localization to caveolae, but we found that alpha1-AR signaling initiated at the nucleus led to activated ERK localized to caveolae. In summary, our results show that nuclear alpha1-ARs transduce signals to caveolae at the plasma membrane in cardiac myocytes.
Wright
Casey D
CD
Cardiovascular Research Center, Sanford Research/USD, Sioux Falls, SD 57105, USA.
Chen
Quanhai
Q
Baye
Nichole L
NL
Huang
Yuan
Y
Healy
Chastity L
CL
Kasinathan
Sivakanthan
S
O'Connell
Timothy D
TD
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D002395:Catecholamines / Q000378:metabolism; D021941:Caveolae / Q000187:drug effects / Q000201:enzymology*; D002458:Cell Fractionation; D002467:Cell Nucleus / Q000187:drug effects / Q000201:enzymology*; D002478:Cells, Cultured; D004268:DNA-Binding Proteins / Q000378:metabolism; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism*; D043802:GTP-Binding Protein alpha Subunits, Gq-G11 / Q000378:metabolism; D049452:Green Fluorescent Proteins / Q000378:metabolism; D008565:Membrane Proteins / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D018613:Microscopy, Confocal; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000201:enzymology*; D027701:Organic Cation Transport Proteins / Q000378:metabolism; D054799:Phospholipase C beta / Q000378:metabolism; D010766:Phosphorylation; D011224:Prazosin / Q000494:pharmacology; D018340:Receptors, Adrenergic, alpha-1 / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013997:Time Factors; D000099254:Organic Cation Transporter 3
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D002395:Catecholamines; D004268:DNA-Binding Proteins; D048049:Extracellular Signal-Regulated MAP Kinases; D043802:GTP-Binding Protein alpha Subunits, Gq-G11; D049452:Green Fluorescent Proteins; D008565:Membrane Proteins; D027701:Organic Cation Transport Proteins; D054799:Phospholipase C beta; D011224:Prazosin; D018340:Receptors, Adrenergic, alpha-1; D011993:Recombinant Fusion Proteins; D000099254:Organic Cation Transporter 3; C547714:Adra1a protein, mouse; C547717:Adra1b protein, mouse; C093413:lamina-associated polypeptide 2; C518034:Plcb1 protein, mouse
N Engl J Med. 1984 Sep 27;311(13):819-23
6382011
J Biol Chem. 1983 Mar 25;258(6):3496-502
6131886
Circulation. 1993 Jun;87(6 Suppl):VI78-87
8500244
J Mol Cell Cardiol. 1993 Sep;25(9):1037-46
8283467
Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):10109-13
7937846
J Neurochem. 1995 Dec;65(6):2387-92
7595531
J Biol Chem. 1996 Apr 19;271(16):9690-7
8621645
Mol Cell Biochem. 1996 Oct-Nov;163-164:181-3
8974055
FEBS Lett. 1998 May 29;428(3):205-11
9654135
J Pharmacol Exp Ther. 1998 Aug;286(2):841-7
9694940
Circ Res. 1999 May 14;84(9):980-8
10325235
Mol Pharmacol. 2005 Apr;67(4):992-1004
15626751
J Clin Invest. 2006 Apr;116(4):1005-15
16585965
Am J Physiol Heart Circ Physiol. 2006 May;290(5):H2059-65
16373581
Handb Exp Pharmacol. 2006;(175):151-80
16722235
Cardiovasc Res. 2006 Jul 1;71(1):69-78
16631628
J Mol Cell Cardiol. 2006 Jul;41(1):17-25
16730745
Circulation. 2007 Feb 13;115(6):763-72
17283256
J Cell Mol Med. 2007 Jul-Aug;11(4):788-97
17760840
Am J Physiol Heart Circ Physiol. 2008 Aug;295(2):H699-707
18552157
JAMA. 2000 Apr 19;283(15):1967-75
10789664
J Biol Chem. 2001 Apr 27;276(17):13738-43
11278430
Circ Res. 2001 Aug 17;89(4):343-50
11509451
Cardiovasc Res. 2001 Sep;51(4):709-16
11530104
Mol Cell Biol. 2001 Nov;21(21):7460-9
11585926
J Mol Cell Cardiol. 2002 Jul;34(7):749-63
12099715
J Biol Chem. 2002 Aug 23;277(34):30429-35
12034720
J Biol Chem. 2002 Sep 13;277(37):34280-6
12097322
J Biol Chem. 2002 Oct 11;277(41):38988-97
12138167
Br J Pharmacol. 2003 Jan;138(1):99-106
12522078
Am J Physiol Heart Circ Physiol. 2003 Apr;284(4):H1104-9
12595294
J Clin Invest. 2003 Jun;111(11):1783-91
12782680
J Biol Chem. 2003 Aug 1;278(31):29153-63
12756260
Hypertension. 2003 Aug;42(2):213-9
12847114
Hypertension. 2003 Sep;42(3):239-46
12925554
J Biol Chem. 2003 Oct 10;278(41):40239-51
12888550
Br J Pharmacol. 2004 Jun;142(4):781-7
15205310
Cardiovasc Res. 2004 Aug 15;63(3):561-72
15276482
J Biol Chem. 1992 Jun 25;267(18):12979-85
1618795